Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥1.24T2024-04-01 → 2024-09-30Cons.Revenue IFRS
Revenue¥2.45T2023-04-01 → 2024-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.19T2023-04-01 → 2023-09-30Cons.Revenue IFRS
Operating income¥121.2bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Operating income−¥133.7bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Profit before tax−¥30.5bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Profit before tax−¥462.8bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥103.8bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Net income (owners)−¥6.5bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥311.8bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥76.3bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥20.3bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Net income−¥465.4bn2023-04-01 → 2024-03-31Cons.Profit loss IFRS (5-year summary)
Net income−¥107.0bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Total assets¥3.72Tat 2024-09-30Cons.Assets IFRS
Total assets¥3.93Tat 2024-03-31Cons.Assets IFRS
Total assets¥4.38Tat 2023-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥2.63Tat 2024-09-30Cons.Liabilities IFRS
Total liabilities¥2.77Tat 2024-03-31Cons.Liabilities IFRS
Net assets / equity¥1.09Tat 2024-09-30Cons.Equity IFRS
Net assets / equity¥1.16Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥1.55Tat 2023-09-30Cons.Equity IFRS
Net assets / equity¥1.49Tat 2023-03-31dCons.Equity IFRS
Equity (owners)¥909.8bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥965.8bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.22Tat 2023-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥273.4bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥217.4bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥277.7bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥305.8bnat 2023-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥63.5bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥51.3bn2023-04-01 → 2024-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥115.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥74.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥112.2bn2023-04-01 → 2024-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥79.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥75.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥49.2bn2023-04-01 → 2024-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥140.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-3.992024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-190.692023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-46.692023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
Equity ratio24.5%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.5%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio27.9%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 62
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2024-09-30¥78.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2024-09-30¥41.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2024-09-30¥37.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2024-09-30¥15.7bn
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥50.2bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥50.2bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥10.0bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2024-04-01 → 2024-09-30¥147.5bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2024-04-01 → 2024-09-30¥138.8bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥8.7bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2024-04-01 → 2024-09-30¥8.7bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2024-04-01 → 2024-09-30¥405.9bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2024-04-01 → 2024-09-30¥403.0bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥2.9bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2024-04-01 → 2024-09-30−¥36.6bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥239.5bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥238.4bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1.1bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥13.6bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2024-04-01 → 2024-09-30¥224.6bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2024-04-01 → 2024-09-30¥224.3bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥235m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2024-04-01 → 2024-09-30¥37.5bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2024-04-01 → 2024-09-30¥195.2bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2024-04-01 → 2024-09-30¥195.2bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1m
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2024-04-01 → 2024-09-30¥470m
—segment totalrevenue2024-04-01 → 2024-09-30¥1.21T
—segment totalrevenue external2024-04-01 → 2024-09-30¥1.20T
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥13.0bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥23.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥76.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥34.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥41.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30¥4.3bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥56.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥56.0bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥7.9bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2023-04-01 → 2023-09-30¥159.8bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2023-04-01 → 2023-09-30¥149.9bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥9.9bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.5bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2023-04-01 → 2023-09-30¥393.1bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2023-04-01 → 2023-09-30¥390.3bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥2.8bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥44.4bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥243.1bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥241.2bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.8bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30−¥7.6bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2023-04-01 → 2023-09-30¥203.9bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2023-04-01 → 2023-09-30¥203.7bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥220m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2023-04-01 → 2023-09-30¥17.8bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥166.9bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥166.9bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1m
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥65.5bn
—segment totalrevenue2023-04-01 → 2023-09-30¥1.17T
—segment totalrevenue external2023-04-01 → 2023-09-30¥1.15T
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥14.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30−¥93.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 919
ItemContextValueUnit
Transactions with non controlling interests ss IFRSCurrentYTDDuration_jpcrp040300-q2r_E00752-000OtherComprehensiveIncomeRelatedToAssetsHeldForSaleIFRSMember-JPY
Transactions with non controlling interests ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-35000000JPY
Transactions with non controlling interests ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember35000000JPY
Transactions with non controlling interests ss IFRSCurrentYTDDuration-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-34603000000JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_jpcrp040300-q2r_E00752-000OtherComprehensiveIncomeRelatedToAssetsHeldForSaleIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration-JPY
Transfers to other comprehensive income related to assets held for sale IFRSCurrentYTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember-JPY
Transfers to other comprehensive income related to assets held for sale IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-150000000JPY
Transfers to other comprehensive income related to assets held for sale IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-150000000JPY
Transfers to other comprehensive income related to assets held for sale IFRSCurrentYTDDuration_jpcrp040300-q2r_E00752-000OtherComprehensiveIncomeRelatedToAssetsHeldForSaleIFRSMember150000000JPY
Transfers to other comprehensive income related to assets held for sale IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-JPY
Transfers to other comprehensive income related to assets held for sale IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-JPY
Transfers to other comprehensive income related to assets held for sale IFRSCurrentYTDDuration-JPY
Total transactions with owners IFRSCurrentYTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember-JPY
Total transactions with owners IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-150000000JPY
Total transactions with owners IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-34753000000JPY
Total transactions with owners IFRSCurrentYTDDuration_jpcrp040300-q2r_E00752-000OtherComprehensiveIncomeRelatedToAssetsHeldForSaleIFRSMember150000000JPY
Total transactions with owners IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-4706000000JPY
Total transactions with owners IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-2734000000JPY
Total transactions with owners IFRSCurrentYTDDuration-7440000000JPY
Equity IFRSCurrentQuarterInstant_EffectivePortionOfCashFlowHedgesIFRSMember221000000JPY
Equity IFRSCurrentQuarterInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember192286000000JPY
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember226235000000JPY
Equity IFRSCurrentQuarterInstant_jpcrp040300-q2r_E00752-000OtherComprehensiveIncomeRelatedToAssetsHeldForSaleIFRSMember150000000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember909751000000JPY
Equity IFRSCurrentQuarterInstant_NonControllingInterestsIFRSMember176744000000JPY
Equity IFRSCurrentQuarterInstant1086495000000JPY
Profit loss before tax IFRSPrior1YTDDuration-103796000000JPY
Profit loss before tax IFRSCurrentYTDDuration-30539000000JPY
Depreciation and amortization ope cf IFRSPrior1YTDDuration78653000000JPY
Depreciation and amortization ope cf IFRSCurrentYTDDuration66812000000JPY
Impairment losses reversal of impairment losses ope cf IFRSPrior1YTDDuration14600000000JPY
Impairment losses reversal of impairment losses ope cf IFRSCurrentYTDDuration253000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration26908000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration-52934000000JPY
Interest and dividend income ope cf IFRSPrior1YTDDuration-10374000000JPY
Interest and dividend income ope cf IFRSCurrentYTDDuration-9140000000JPY
Interest expenses ope cf IFRSPrior1YTDDuration14529000000JPY
Interest expenses ope cf IFRSCurrentYTDDuration14682000000JPY
Business structure improvement expenses ope cf IFRSPrior1YTDDuration22121000000JPY
Business structure improvement expenses ope cf IFRSCurrentYTDDuration11702000000JPY
Loss gain on sale of fixed assets ope cf IFRSPrior1YTDDuration-818000000JPY
Loss gain on sale of fixed assets ope cf IFRSCurrentYTDDuration-10717000000JPY
Decrease increase in trade receivables ope cf IFRSPrior1YTDDuration47604000000JPY
Decrease increase in trade receivables ope cf IFRSCurrentYTDDuration60218000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass